Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/1999
11/30/1999US5994537 Process for preparing azepinone compounds useful in the inhibition of ACE and NEP
11/30/1999US5994397 Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
11/30/1999US5994379 Analgesics; antiinflammatory agent; antipyretics
11/30/1999US5994350 Cardiovascular disorders; central nervous system disorders; gastrointestinal disorders; respiratory system disorders
11/30/1999US5994312 Peptidyl compounds
11/30/1999US5994293 Peptidyl compounds and their therapeutic use
11/30/1999US5994111 A polypeptide; treatment and diagnosis of respiratory infections, septic arthritis, cardiovascular infections, gastrointestinal infections, toxic shock syndrome; antibiotics
11/30/1999US5994096 Regulator
11/30/1999US5993814 Agents for inhibition of chemoattractant
11/30/1999CA2179011C 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
11/25/1999WO1999059992A1 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
11/25/1999WO1999059975A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999WO1999059973A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999WO1999059620A1 Angiostatin receptor
11/25/1999WO1999059499A2 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
11/25/1999WO1999050249A3 Pyrimidines and triazines as integrin antagonists
11/25/1999CA2332507A1 Angiostatin receptor
11/25/1999CA2332505A1 Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders
11/25/1999CA2332279A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999CA2332239A1 Fused tricyclic compounds which inhibit parp activity
11/24/1999EP0958282A1 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
11/24/1999EP0957929A1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
11/24/1999EP0957901A1 Pharmaceutical preparations of glutathione and methods of administration thereof
11/24/1999CN1236354A Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cometic compositions containing same
11/24/1999CN1046732C Enantioselective synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-methyl-4H-thieno [2,3-b] thiopyran-2-sulfonamide 7,7-dioxide and related compounds
11/24/1999CN1046722C Heterocyclic compounds and their preparation and use
11/24/1999CN1046721C Heterocyclic compounds and their preparation and use
11/24/1999CN1046718C 6-(2-imidzolinylamino) quinoline compounds useful as alpha-2-adrenoceptor agonists
11/24/1999CN1046711C Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
11/23/1999US5990280 Factor which is heat resistant but sensitive to acidic and alkaline conditions, does not bind heparin, induced by wild type p53 expression, is not thrombospondin, molecular weight of about 100 kilodaltons; diagnosis, anticarcinogenic agents
11/23/1999US5990170 Possesses a profile of activity which is similar to, though less potent than .delta.9-thc (tetrahydrocannabinol) with a mimicking of the psychoactive effects; analgesics; side effect reduction; cardiovascular disorders
11/23/1999US5990158 Carboxylic acid derivatives, method of manufacturing the same and therapeutic agents containing these compounds
11/23/1999US5990148 Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents
11/23/1999US5990145 Antiinflammatory,-carcinogenic,-tumor,-metastasis agents; cardiovascular disorders, e.g., arteriosclerosis, restenosis; retinopaathies and nephropathies; osteoporosis
11/23/1999US5990142 Antiinflammatory agents and antiallergens having good oral adsorption and bioavailability; cardiotonic and antiischemic agents
11/23/1999US5990138 Cyclopentane (ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
11/23/1999US5990127 Process for the preparation of 4-(4-(4-(hydroxybiphenyl)-1-piperidinyl)-1-hydroxybutyl)-α,α -dimethylphenylacetic acid and phosphorylated derivatives
11/23/1999US5990103 Treating psoriasis by topical adminstration of pentoxifylline and diltiazem to a patient; a combination of a compound having a phosphodiesterase-inhibiting action, and a compound which reduces the intracellular calcium content
11/23/1999US5990099 Treating glc1a glaucoma by administering an angiostatic steroid of given formula
11/23/1999US5989864 DNA encoding spo-rel polypeptides
11/23/1999US5989558 Extracting leaves with aqueous ethanol
11/18/1999WO1999058531A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999WO1999058528A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999WO1999058523A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
11/18/1999WO1999058160A1 The use of a vital dye for facilitating surgical procedures for cataract extraction
11/18/1999WO1999058139A2 Methods for detecting and inhibiting angiogenesis
11/18/1999WO1999058131A1 Use of tetracyclines for treating meibomian gland disease
11/18/1999WO1999058096A2 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
11/18/1999WO1999028475A3 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
11/18/1999CA2331878A1 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
11/18/1999CA2330108A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999CA2330095A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999CA2328414A1 Methods for detecting and inhibiting angiogenesis
11/17/1999EP0956289A1 Novel prokaryotic polynucleotides, polypeptides and their uses
11/17/1999EP0956043A1 Strain selection of pneumococcal surface proteins
11/17/1999EP0956038A1 Morphogen peptide-induced regeneration of sense perceptory tissues
11/17/1999CN1046512C Mercaptoacetylamide disulfide derivatives, preparation thereof and medicinal composition containing the same
11/17/1999CN1046505C Preparation of 1-benzyl-3-hydroxymethyl-indazole and ether of aliphatic-2-hydroxy acid
11/16/1999US5985937 Leukotriene mediated disease in humans for enzyme inhibitors
11/16/1999US5985928 Bioactive bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
11/16/1999US5985920 Difluoroprostaglandin derivatives and their use
11/16/1999US5985902 Substituted isoxazole for the treatment of inflammation
11/16/1999US5985894 Useful in the treatment of cardiovascular illnesses
11/16/1999US5985881 Treatment and prevention of respiratory disorders, inflammatory eye diseases, inflammatory skin diseases, intestinal disorders, other inflammatory diseases
11/16/1999US5985857 Generating stable protein-sugar post-amadori advanced glycation end-product (age) intermediates comprising incubating protein with pentose sugar
11/16/1999CA2169481C Method of inhibiting nitric oxide formation
11/11/1999WO1999057152A1 Oral administration of immunoglobulins for treating autoimmune hearing loss
11/11/1999WO1999057115A1 Novel benzimidazoles and benzoxazoles
11/11/1999WO1999056763A1 Use of neglected target tissue antigens in modulation of immune responses
11/11/1999WO1999056737A1 Arylhydrocarbon receptor ligand antagonists
11/11/1999WO1999040083A3 Bifunctional tryptase inhibitors
11/11/1999WO1999040073A3 Tryptase inhibitors
11/11/1999CA2331738A1 Oral administration of immunoglobulins for treating autoimmune hearing loss
11/11/1999CA2331364A1 Arylhydrocarbon receptor ligand antagonists
11/11/1999CA2331037A1 Novel benzimidazoles and benzoxazoles
11/11/1999CA2329704A1 Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
11/11/1999CA2328108A1 Use of neglected target tissue antigens in modulation of immune responses
11/10/1999EP0955294A2 Imidazolyl-alkenoic acid
11/10/1999EP0954535A1 Antibodies that bind to the nidogen-binding domain of laminin, their production and use
11/10/1999EP0954519A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
11/10/1999EP0954305A2 Use of carbonic anhydrase inhibitors for treating macular edema
11/10/1999EP0954302A1 Therapeutic methods and compositions involving isoflavones
11/10/1999EP0954281A1 Moistening preparation
11/10/1999EP0954222A1 Gene therapy for proliferative vitreoretinopathy
11/10/1999EP0863873B1 Indole carbamates as leukotriene antagonists
11/10/1999CN1234791A Inhibition of matrix metalloproteases by 2-('omega'-aroylalkyl)-4-biaryl-oxobutyric acids
11/10/1999CN1234396A Process for alkylation of hindered sulfamide
11/10/1999CN1234274A Medicine for treatment of myopia
11/10/1999CN1234229A Apparatus for treatment of immunomediated inflammatory disorders
11/09/1999US5981776 Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
11/09/1999US5981762 Substituted indole-2-carboxylic acids as glucosyl transferase inhibitors
11/09/1999US5981755 Tachykinin antagonists
11/09/1999US5981598 Administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma
11/09/1999US5981574 Phenanthrofuran derivatives
11/09/1999US5981572 Treatment of disorders which arise from a disturbed functioning of systems which are regulated by melatonin; in particular in the treatment of chronobiological disorders, especially in the elderly
11/09/1999US5981491 Peptides; metalloenzymes; tumor necrosis factor
11/09/1999US5981490 Peptidyl compounds
11/09/1999US5981483 Compositions comprising modulators of cytokines of the TGF-β superfamily
11/09/1999US5980887 Methods for enhancing angiogenesis with endothelial progenitor cells
11/09/1999US5980865 Administering to the patient of a pharmaceutical composition containing about 0.005 to about 1.0 mg of ultra-low molecular weight heparins
1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 531